Three quarters of all breast cancers are positive for expression of estrogen receptor alpha (ERα), encoded by the ESR1 gene3, making ER signaling the most important target of clinical treatments in ERα-positive BC. This evidence concerns the gene ESR1 and breast carcinoma.